CA19-9 Antibody | V3057IHC-7ML

CA19-9 Antibody | V3057IHC-7ML | Gentaur US, UK & Europe Disrtribition

Family: Primary antibody

Formulation: Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*

Format: Purified

Clone: 121SLE

Host Animal: Mouse

Clonality: Monoclonal (mouse origin)

Species Reactivity: Human

Application: IHC-P

Buffer: N/A

Limitation: This CA19-9 antibody is available for research use only.

Purity: PEG precipitation

Description: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.

Immunogen: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Storage: Store the CA19-9 antibody at 2-8oC (with azide) or aliquot and store at -20 °C or colder (without azide).